Major Depressive Disorder and Food Hypersensitivity: A Case Report

2019 ◽  
Vol 78 (4) ◽  
pp. 249-255
Author(s):  
Monique Aucoin ◽  
Sukriti Bhardwaj
Keyword(s):  
Major Depressive Disorder ◽  
Case Report ◽  
Depressive Disorder ◽  
Food Hypersensitivity ◽  
Major Depressive

Psychiatric shades of grey: mirtazapine-induced hair discoloration and hair loss

2016 ◽  
Vol 33 (3) ◽  
pp. 175-178 ◽  
Author(s):  
M. Osman ◽  
M. D. McCauley
Keyword(s):  
Major Depressive Disorder ◽  
Case Report ◽  
Adverse Effects ◽  
Depressive Disorder ◽  
Hair Loss ◽  
Temporal Relationship ◽  
Relevant Literature ◽  
Major Depressive ◽  
Hair Colour ◽  
Medical Reason

IntroductionMirtazapine is indicated in the treatment of major depressive disorder particularly in selective serotonin re-uptake inhibitors resistance. Its effect on hair loss is rare with no previous documented effect on hair colour.MethodReview of relevant literature and description of a case report of a 54-year-old male patient who developed alopecia and hair discoloration after initiation of mirtazapine treatment.ResultsUpon cessation of mirtazapine treatment full restoration of hair colour and regrowth of hair was attained within 10 weeks.DiscussionThere was clear temporal relationship between experiencing hair loss and commencing mirtazapine treatment. No other more likely medical reason to explain such experience was established. A noticeable restoration of the hair colour occurred following mirtazapine cessation.ConclusionMirtazapine is associated with hair discoloration and hair loss. The possibility of such distressing adverse effects needs to be conveyed to patients by clinicians and to be further explored by researchers.

Brain Biopsy Findings Link Major Depressive Disorder to Neuroinflammation, Oxidative Stress, and Neurovascular Dysfunction: A Case Report

2014 ◽  
Vol 75 (12) ◽  
pp. e23-e26 ◽  
Author(s):  
Souhel Najjar ◽  
Daniel M. Pearlman ◽  
Scott Hirsch ◽  
Kent Friedman ◽  
John Strange ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Major Depressive Disorder ◽  
Case Report ◽  
Depressive Disorder ◽  
Brain Biopsy ◽  
Major Depressive ◽  
Neurovascular Dysfunction

scholarly journals Transitory restless arms syndrome in a patient with antipsychotics and antidepressants: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Juan Chen ◽  
Na Meng ◽  
Bingrong Cao ◽  
Yinghua Ye ◽  
Ying Ou ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Case Report ◽  
Clinical Practice ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Case Presentation ◽  
First Choice ◽  
Patient Reported ◽  
Sustained Release Tablets ◽  
Medication Adjustment

Abstract Background Restless arms syndrome (RAS) is characterized by uncomfortable aching or burning sensations in the arms. RAS is regarded as an upper limb variant of restless legs syndrome (RLS). The lack of specific diagnostic criteria makes it difficult to recognize the RAS. Therefore, RAS is usually neglected in clinical practice. Moreover, when a patient was diagnosed with RAS, the adjustment of medications was the first choice for doctors, which may make the patient’s condition unstable. Case presentation A 33-year-old woman was diagnosed with schizophrenia and major depressive disorder. Starting with 0.6 g/d amisulpride, 0.1 g/d quetiapine, 75 mg/d venlafaxine sustained-release tablets, the patient reported symptoms of RAS (itching arms) on the fourth day since the latest hospitalization. After ruling out other factors, her RAS was suspected to be induced by antidepressants or antipsychotics. Without medication adjustment, RAS spontaneously remitted. Conclusions This case suggests that psychiatrists should pay attention to RAS when using antipsychotics and/or antidepressants. Moreover, RAS may be transitory. When a patient manifests RAS, observation may be one choice instead of an immediate medication adjustment.

Sign in / Sign up

Export Citation Format

Share Document